Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Archive
- 2024/Volume 45
- 2023/Volume 44
- 2022/Volume 43
- 2021/Volume 42
- 2020/Volume 41
- 2019/Volume 40
- 2018/Volume 39
- 2017/Volume 38
- 2016/Volume 37
- 2015/Volume 36
- 2014/Volume 35
- 2013/Volume 34
- 2012/Volume 33
- 2011/Volume 32
- 2011/Volume 31
- 2009/Volume 30
- 2008/Volume 29
- 2007/Volume 28
- 2006/Volume 27
- 2005/Volume 26
- 2004/Volume 25
- 2003/Volume 24
- 2002/Volume 23
- 2001/Volume 22
- 2000/Volume 21
Molecular Markers in Ovarian Cancer: Roles in Diagnosis, Prognostic Prediction, and Personalized Therapy
Deadline for manuscript submissions: 30 March 2022
Print Special Issue Flyer (5)Special Issue Editor
Guest Editor
Sharad Ghamande, MDE-MailWebsite
Department of Obstetrics and Gynecology, Augusta University, Augusta, USA
Interests: Ovarian Cancer
Guest Editor
Department of Obstetrics and Gynecology, Augusta University, Augusta, USA
Interests: Ovarian Cancer
Special Issue Information
Dear Colleagues,
Ovarian cancer is a lethal female malignancy with more than 14,000 deaths per year in United States. This is related to the fact that most patients are diagnosed at an advanced stage. While over the years there has been a focus on trying to diagnose this neoplasm in its earliest stages to improve outcomes; there has been an explosion of over 10 new FDA approved therapies during the last 15 years for this disease. However, outside of BRCA mutation status and PARP inhibitors, molecular markers to guide therapeutic decision making have been sparse.
In this special issue, authors will present studies focusing on molecular markers which improve early detection, prognostic predictions, and personalized therapies. Studies may also focus on how molecular markers predict cytoreductive surgery outcomes, and response to platinum-based chemotherapies and intra peritoneal therapy.
Special consideration will be given to studies focusing on prognosis or prediction of response to PARP inhibitors, immunotherapies, and treatments inhibiting angiogenesis. Reports investigating markers of the effectiveness of FDA approved drugs not yet approved for ovarian cancer may also be considered in this special issue.
Prof. Sharad Ghamande and Dr. David Mysona
Guest Editors
Keywords
Ovarian Cancer;Diagnosis;Prognosis;Treatment Response;Personalized Therapy;Platinum Resistance;Homologous Recombination Deficiency;Immunotherapy;Cytoreduction;Proteomics;Genomics;Prognostic Biomarkers;Diagnostic Biomarkers
Manuscript Submission Information
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Share This Special Issue
Published Papers (1 papers)
Prognostic value of matrix metalloproteinase 2 protein expression in ovarian cancer is age- and stage-dependent
Prognostic value of matrix metalloproteinase 2 protein expression in ovarian cancer is age- and stage-dependent
DOI: 10.31083/j.ejgo4301010
(This article belongs to the Special Issue Molecular Markers in Ovarian Cancer: Roles in Diagnosis, Prognostic Prediction, and Personalized Therapy)
Abstracted / indexed in
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.